The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal
Open Access
- 6 September 2017
- journal article
- review article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 43 (1) , 173-194
Abstract
Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.Keywords
This publication has 107 references indexed in Scilit:
- Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trialDrug and Alcohol Dependence, 2011
- Double-blind fluoxetine trial in comorbid MDD–CUD youth and young adultsDrug and Alcohol Dependence, 2010
- Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapsePsychopharmacology, 2010
- Opioid antagonism enhances marijuana's effects in heavy marijuana smokersPsychopharmacology, 2010
- A placebo-controlled trial of buspirone for the treatment of marijuana dependenceDrug and Alcohol Dependence, 2009
- Attempts to stop or reduce marijuana use in non-treatment seekersDrug and Alcohol Dependence, 2008
- Controversies in translational research: drug self-administrationPsychopharmacology, 2008
- A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substancesDrug and Alcohol Dependence, 2008
- Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapsePsychopharmacology, 2007
- Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis usersPsychopharmacology, 2007